Allogeneic hematopoietic cell transplantation (alloHCT) with myeloablative conditioning based on total body irradiation (TBI) is widely used for the treatment of adults with acute lymphoblastic leukemia (ALL).
| I N TR ODU C TI ON
Allogeneic hematopoietic stem cell transplantation (alloHCT) is widely used for the treatment of adults with Philadelphia-negative (Ph-negative) acute lymphoblastic leukemia (ALL). The anti-leukemic effect and thus curative potential of alloHCT in ALL is associated with both the conditioning regimen and the graft versus leukemia (GvL) effect. [1] [2] [3] However, specifically in ALL the conditioning regimen may be of special importance, due to very aggressive nature of the disease and therefore more confined and debated efficacy of GvL effect as compared with other hematological malignancies. 1, 3, 4 Although the optimal pretransplantation conditioning has never been established in randomized trials, results of many retrospective studies, including recently published large analysis by the European Society for Blood and Marrow Transplantation (EBMT) suggested advantage of total body irradiation (TBI)-based over chemotherapy-based regimens, in terms of reduced risk of relapse and improved leukemia-free survival (LFS). 5, 6 TBI was demonstrated to be superior to conditioning consisting of busulfan and Cy (BuCy), especially in young patients with T-ALL 7 as well as those with refractory disease. 8 TBI is most frequently administered in combination with either cyclophosphamide (Cy/TBI) or etoposide (Vp/TBI), however, there was only one retrospective study comparing Cy/TBI with Vp/TBI in adult ALL patients treated with
alloHCT from HLA-compatible sibling. The optimal combination of TBI and chemotherapy should therefore be further explored.
The aim of this large retrospective EBMT registry study was to compare the outcomes of patients with ALL receiving alloHCT from HLA-compatible sibling or matched unrelated donors after TBI in combination with cyclophosphamide (Cy/TBI) with those transplanted after TBI combined with etoposide (Vp/TBI).
| M A TE RI A L A ND M E TH ODS

| Study design and data collection
This is a retrospective registry based analysis on behalf of the ALWP of EBMT. The EBMT is a voluntary working group of more than 500 transplant centers that are required to report all consecutive stem cell transplantations and follow-ups once a year. The validation and quality control program includes verification of the computer print-out of the entered data, cross-checking with the national registries, and on-site visits of selected teams. This study was approved by the ALWP of the EBMT institutional review board. The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. All patients provided written informed consent authorizing the use of their personal information for research purposes.
| Data source and patient eligibility
Data for this analysis were obtained from the ALWP registry of the EBMT. We identified adult patients with Ph-negative ALL in first or second complete remission (CR1 or CR2) who underwent first alloHCT from geno-identical sibling or unrelated donors after myeloblative Cy/ TBI or Vp/TBI conditioning between 2000 and 2015. Patients with secondary ALL were excluded from the current analysis, as well as patients receiving or that had received in the past cord blood transplants and ex vivo T cell depletion.
| Study endpoints and definitions
LFS was selected as the primary study endpoint. The secondary endpoints were relapse incidence (RI), nonrelapse mortality (NRM), acute and chronic graft versus host disease (aGvHD and cGvHD) incidence, overall survival (OS), as well as GvHD and relapse-free survival (GRFS).
LFS was measured from the time of transplantation until relapse or death from any cause. Overall survival was measured from the time of transplantation until death of any cause. For GRFS events were defined as grade 3-4 acute GVHD, systemic therapy-requiring chronic GVHD, relapse, or death from any other reason. 9 LFS was selected as the primary endpoint, other outcomes being secondary endpoints. were treated more frequently in CR1 (87% vs. 78%, P 5 .014). The study groups did not differ with respect to other characteristics.
| Statistical analysis
| Engraftment
Engraftment was comparable between the two study groups. The median time to ANC0.5 3 10 9 in the Cy/TBI group was 18 (range, 2-66) days, compared to 19 (range, 7-56) days in the Vp/TBI group (p NS). Graft failure occurred in 2.4% of the patients that were conditioned with Cy/TBI and in 0.7% patients who received Vp/TBI conditioning, respectively.
| Acute and chronic GvHD
There were no significant differences in the incidence of acute or chronic GvHD between patients conditioned with Cy/TBI and Vp/TBI (Supporting Information). The cumulative incidences of aGvHD grade II-IV were 39% in both groups. Chronic GvHD rates were also comparable between the patients that received Cy/TBI and those that were conditioned with Vp/TBI (15% vs 17%, P 5 .49).
| Survival
The median follow-up of surviving patients was 60 months (range, 1-
months). At 5 years post transplantation, estimated LFS and OS
were 51.2% (95% CI: 48.5-53.9) and 54.9% (95% CI: 52.1-57.7) for the whole study group, respectively. In a univariate analysis, as compared to Cy/TBI, the use of Vp/TBI was associated with significantly higher LFS (60% vs. 50%, P 5 .04) ( Figure 1 ) and GRFS (43% vs 32%, P 5 .035) (Supporting Information). However, the study groups did not differ with respect to OS.
| Relapse incidence and nonrelapse mortality
Patients conditioned with Vp/TBI had a significantly reduced incidence of relapse at 5 years as compared to patients conditioned with Cy/TBI (17% vs. 30%, P 5 .007) ( Figure 2 ). While, the cumulative incidence of NRM was comparable between the two groups (20% vs. 23%, P 5 .79).
| Multivariate analysis for the whole study group
Details on the multivariate analysis are presented in Table 2 . The use of Vp/TBI was associated with reduced risk of relapse (HR 5 0.62, and disease stage (CR1 vs. CR2) had significant impact on RI, NRM, LFS, OS and GRFS. Increasing age of recipient was associated with increased risk of NRM as well as lower LFS, OS and GRFS. In addition, the risk of relapse was higher in patients transplanted from sibling vs.
unrelated donors (HR 5 1.47, P 5 .01) and in donor/recipient gender combination other than female/male (HR 5 1.37, P 5 .04). On the contrary, GRFS was higher for patients who received graft from sibling as compared to unrelated donors and for female patients. GRFS was also higher in CMV negative patients and in those who received in vivo TCD.
| D ISC USSION
The optimal conditioning for patients with Ph-negative ALL undergoing alloHCT remains undetermined due to the lack of prospective, randomized trials. However, the use of 12 to 13.2 Gy of TBI in the pretransplantation conditioning is preferred in young, adult patients based on the results of numerous retrospective analyzes demonstrating superior transplantation outcomes in comparison to radiation-free regimens. [11] [12] [13] The historical retrospective analysis performed by the ALWP of the EBMT included patients with acute leukemias treated with either autologous (auto) or allogeneic HCT. 14 A subgroup analysis performed in ALL patients showed higher antitumor efficacy of TBI in comparison with BuCy in patients undergoing autoHCT. Thereafter, Cy/TBI was demonstrated to be superior to oral busulfan based conditioning in terms of the OS and LFS after alloHCT, regardless of the 4 In that study including only patients undergoing alloHCT from HLAidentical siblings the beneficial anti leukemic effect of the etoposide/ TBI combination reducing relapse rate was demonstrated but it was restricted to patients transplanted in CR2.
All past retrospective analyzes, evaluating the efficacy of various conditioning regimens for ALL included patients diagnosed with both Ph-positive and Ph-negative ALL. However, dissecting the effect of the pre transplantation conditioning on alloHCT outcome and especially post-transplant relapse incidence in Ph-positive ALL will be more difficult due to the widespread use of tyrosine kinase inhibitors (TKIs) preemptively or prophylactically post-transplant. Obviously the TKIs may reduce the risk of relapse independently of the pretransplant conditioning. 18 Therefore in the current study, we restricted the analyzed population and focused on a relatively homogenous group of patients with Ph-negative ALL. Additional difference in comparison to previous reports is that we included patients undergoing transplantation from HLA-identical siblings but also from unrelated donors as the number of transplants from unrelated donors for ALL are constantly increasing in Europe. 5 In the current study, we were able to demonstrate that Vp/ TBI was associated with significant reduction of the risk of relapse as compared to Cy/TBI as illustrated in both univariate and multivariate analysis. Notably as the vast majority of patients in the current study 
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were transplanted in CR1, the reduced relapse rate we observed with the Vp/TBI regimen includes patients with early stage disease which is of importance and rather novel as the previous study by Marks et al. who demonstrated advantage of Vp/TBI only for patients treated in CR2. 4 Furthermore, the results of our current study also confirm that Vp/ TBI conditioning is feasible and does not increase graft failure, NRM, nor GvHD incidence. This finding is of importance especially as the historical data suggested that substitution of Cy by less immunosuppressive compound like Vp may result in more frequent engraftment failures. 19 Of note, in our study only one patient experienced graft failure after conditioning with Vp/TBI and the graft failure rate did not differ between patients conditioned with Vp/TBI versus those receiving Cy/TBI. Some concerns were also associated with severe mucositis reported after Vp/TBI treatment. 20 Lack of detailed information on toxicities is one of the limitation of our retrospective study. It should be noted, however, that NRM after Vp/TBI and Cy/TBI was comparable in our analysis.
Although TBI based conditioning is considered a standard, it should be mentioned that it is associated with the risk of both early and late adverse effects. [21] [22] [23] Late complications include, among others, cataract, infertility, interstitial pneumonitis and secondary malignancies, which may severely affect both the quality of life and lifespan. 22, 24 Therefore, ongoing attempts are focusing on elaborating radiation-free regimens that would provide anti leukemic efficacy comparable to those achieved by TBI. Results of a recently published matched-pair analysis from the EBMT registry suggest that outcome with thiotepabased conditioning may be comparable to those achieved by Cy/TBI for adults with early, but not with advanced ALL. 25 However, in view of the current findings Vp/TBI should probably be considered more appropriate comparator for such retrospective and future prospective studies. Furthermore, long-term safety of thiotepa-based regimens still need to be explored with longer follow-up.
As our analysis was a retrospective registry-based study, some limitation had to be accepted, such as lack of detailed information on the patients' cytogenetic profile, minimal residual disease status and toxicities. The information on translocation (4;11) was available for only 60% of patients conditioned with Cy/TBI and 63% of those conditioned with Vp/TBI. Moreover, it should be emphasized that myeloablative TBI may vary in terms of doses, fractionation, dose rates, .002
aGVHD, acute GvHD; cGvHD, chronic GvHD; Cy/TBI, cyclophosphamide/total body irradiation; GRFS, GVHD/relapse-free survival; GvHD, graft versus host disease; LFS, leukemia-free survival; NRM, nonrelapse mortality; OS, overall survival; RI, relapse incidence; Vp, etoposide.
radiation sources and organ shielding, 23 parameters that were not available in the EBMT registry, and therefore could not be adequately controlled for in the analysis.
In conclusion, the results of our study indicate that conditioning regimen based on etoposide combined with TBI appears more effective in terms of relapse than the combination of cyclophosphamide with TBI for adult patients with Ph-negative ALL undergoing alloHCT. Further, prospective studies are needed to confirm our observation and potentially discriminate subgroup of patients who are most likely to benefit from the use of etoposide TBI combination.
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